Albany, NY -- (SBWIRE) -- 06/21/2017 -- Intragastric balloons are gastric balloons made of soft biocompatible silicone material generally filled with sterile saline solutions or gas. These are inserted into the stomach through a non-surgical endoscopic process. An intragastric balloon when inflated would reduce the volume of stomach making a person feel fuller quicker and longer. It would also reduce the amount of food intake. This procedure is an option for overweight and obese persons with a body mass index (BMI) ranging from 30 to 70 who are not eligible for weight loss surgery. Permanent healthy changes to diet and exercise is required to ensure success of the intragastric balloon procedure. Primary advantage of this procedure is it helps avoid the risk associated with surgical procedures. However, few disadvantages are that it is not tolerated by all patients and risk of nausea and vomiting. These balloons may also lead to failure of weight loss if a patient does not stick to the diet and exercise.
Obesity is a complex metabolic illness resulting from the accumulation of excessive fat in the body leading to critical health conditions. It is now the new epidemic. According to WHO, over 1 billion people are overweight in the world, of these 50% are severely obese. Obese patients have high chances of developing serious medical conditions such as cardiovascular diseases, diabetes mellitus, stroke, and liver diseases. Studies have shown that these life threatening medical conditions can be improved by weight loss.
Major drivers of the intragastric balloons market are preference for minimally invasive technique, non-eligibility of obese patients for the surgical procedure, increased commercial availability of the product, and rise in prevalence of obesity due to diet and lifestyle changes. However, non-coverage of the endoscopic intragastric balloon procedure in insurance, and other side effects such as gastric erosion, development of gastric ulcers, nausea, and vomiting act as major restraints of the intragastric balloons market. Technological advancement and innovation along with reduced cost of the procedure are anticipated to propel the intragastric balloons market.
View Report-
http://www.transparencymarketresearch.com/intragastric-balloons-market.html
In terms of product type, the intragastric balloons market has been segmented into single, dual and triple intragastric balloons. The triple intragastric balloons segment is anticipated to be driven by increased weight loss and insertion with less invasive procedures.
Based on filling material, the intragastric balloons market has been segmented into saline filled and gas filled. Introduction of colored sterile saline solution as filler is likely to boost the growth of the market as it helps early detection of deflated balloon, thus avoiding the risk of surgical procedure for removal of the deflated balloon from the intestine. Gas balloons are bacterial resistant and are layered which reduce the risk of deflation of balloons.
In terms of end-user, the intragastric balloons market has been categorized into hospitals, ambulatory clinical services, and clinics. The hospitals segment is anticipated to witness significant growth due to availability of highly skilled professionals and funding.
In terms of region, the intragastric balloons market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. According to data provided by the WHO, over 50% of the world's population was overweight or obese in 2014. Obesity is higher in regions with large high-income group population. Hence, North America is anticipated to be the fastest growing market, followed by Asia Pacific where the number of people suffering from obesity is increasing significantly. According to the WHO, top five countries with high obese population are the U.S., China, India, Russia, and Brazil.
Key players in the intragastric balloons market are Allurion Technologies, Apollo Endosurgery, Districlass Medical, Helioscopie Medical Implants, Silimed, Lexel, Medsil, Obalon Therapeutics, ReShape Medical, Spatz, Life Partners Europe, and Tulip Medical.
The study is a source of reliable data on:
Market segments and sub-segments
Market trends and dynamics
Supply and demand
Market size
Current trends/opportunities/challenges
Competitive landscape
Technological breakthroughs
Value chain and stakeholder analysis
The regional analysis covers:
North America (U.S. and Canada)
Latin America (Mexico, Brazil, Peru, Chile, and others)
Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
Eastern Europe (Poland and Russia)
Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)
Middle East and Africa (GCC, Southern Africa, and North Africa)
Request a brochure of this report to know what opportunities will emerge in the rapidly evolving Intragastric Balloons Market during 2017- 2025
http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=26006